These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32594931)

  • 1. Dopamine D
    Hernández-Huerta D; Morillo-González J
    CNS Spectr; 2021 Oct; 26(5):444-445. PubMed ID: 32594931
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder.
    Grunze H
    Expert Opin Pharmacother; 2023; 24(18):1985-1992. PubMed ID: 37817489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of dopamine D
    Calabrese F; Tarazi FI; Racagni G; Riva MA
    CNS Spectr; 2020 Jun; 25(3):343-351. PubMed ID: 31010452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
    Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
    CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of cariprazine.
    Stahl SM
    CNS Spectr; 2016 Apr; 21(2):123-7. PubMed ID: 26956157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.
    Takase M; Kanahara N; Oda Y; Kimura H; Watanabe H; Iyo M
    J Psychopharmacol; 2015 Apr; 29(4):383-9. PubMed ID: 25735995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Worsening of psychosis in a 30 year old man with undifferentiated schizophrenia.
    Ahuja N; Lloyd AJ
    Ann Clin Psychiatry; 2008; 20(2):113-4. PubMed ID: 18568584
    [No Abstract]   [Full Text] [Related]  

  • 9. Aripiprazole as a dopamine partial agonist: positive and negative effects.
    Glick ID; Duggal V; Hodulik C
    J Clin Psychopharmacol; 2006 Feb; 26(1):101-3. PubMed ID: 16415723
    [No Abstract]   [Full Text] [Related]  

  • 10. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1165-78. PubMed ID: 21087552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
    Citrome L
    Int J Clin Pract; 2015 Nov; 69(11):1211-20. PubMed ID: 26477545
    [No Abstract]   [Full Text] [Related]  

  • 12. Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?
    Crismon ML; DeLeon A; Miller AL
    Ann Pharmacother; 2003 May; 37(5):738-40. PubMed ID: 12708954
    [No Abstract]   [Full Text] [Related]  

  • 13. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
    Costentin J
    Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
    Reynolds GP
    J Psychopharmacol; 2021 Sep; 35(9):1030-1036. PubMed ID: 34256637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy.
    Inoue A; Nakata Y
    Jpn J Pharmacol; 2001 Aug; 86(4):376-80. PubMed ID: 11569610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.
    Newman AH; Grundt P; Nader MA
    J Med Chem; 2005 Jun; 48(11):3663-79. PubMed ID: 15916415
    [No Abstract]   [Full Text] [Related]  

  • 17. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
    Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma.
    Freeman B; Levy W; Gorman JM
    J Psychiatr Pract; 2007 Mar; 13(2):120-4. PubMed ID: 17414690
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia.
    Buckley PF
    J Subst Abuse Treat; 1998; 15(2):113-6. PubMed ID: 9561949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.